Published in Immunol Rev on November 01, 2015
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab (2016) 0.83
Autoimmune synaptopathies. Nat Rev Neurosci (2016) 0.82
IgG1 and IgG4 anti-CCP associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project). Clin Exp Immunol (2016) 0.79
Balancing Tolerance or Allergy to Food Proteins. Trends Immunol (2016) 0.76
Room temperature structure of human IgG4-Fc from crystals analysed in situ. Mol Immunol (2016) 0.75
The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy. Curr Allergy Asthma Rep (2016) 0.75
Pulmonary manifestation of immunoglobulin G4-related disease in a 7-year-old immunodeficient boy with Epstein-Barr virus infection: a case report. Ital J Pediatr (2016) 0.75
Pathological manifestations in lymphatic filariasis correlate with lack of inhibitory properties of IgG4 antibodies on IgE-activated granulocytes. PLoS Negl Trop Dis (2017) 0.75
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
IgG4-related disease. N Engl J Med (2012) 15.76
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
IgG Fc receptors. Annu Rev Immunol (2001) 8.63
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry (1981) 6.13
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science (2001) 5.39
Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature (1985) 5.32
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2000) 5.18
IgE in allergy and asthma today. Nat Rev Immunol (2008) 4.67
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
Convergent solutions to binding at a protein-protein interface. Science (2000) 4.47
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol (1983) 4.02
The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature (2000) 3.53
Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med (1995) 3.38
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol (2003) 3.25
Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet (2001) 3.06
Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature (1994) 2.85
Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med (2011) 2.80
Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell (2001) 2.67
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
Immunoglobulin G4: an odd antibody. Clin Exp Allergy (2009) 2.59
Properties of mouse and human IgG receptors and their contribution to disease models. Blood (2012) 2.53
Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 2.52
Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A (2007) 2.49
FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol (2010) 2.44
The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 2.33
Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med (2012) 2.30
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res (2014) 2.26
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol (2000) 2.25
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J (2012) 2.11
Refined structure of an intact IgG2a monoclonal antibody. Biochemistry (1997) 2.02
Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol (1998) 1.99
Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol (2006) 1.99
IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol (1998) 1.98
IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 1.95
IgG4 breaking the rules. Immunology (2002) 1.93
Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol (2004) 1.91
Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature (2000) 1.90
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol (2007) 1.89
Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov (2011) 1.89
The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med (1991) 1.88
Human FcγRIIA induces anaphylactic and allergic reactions. Blood (2011) 1.86
Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure (1995) 1.86
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci (2009) 1.79
IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest (2006) 1.77
The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol (2014) 1.75
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 1.73
Identity of the elusive IgM Fc receptor (FcmuR) in humans. J Exp Med (2009) 1.72
TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci U S A (2008) 1.72
General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A (2013) 1.69
Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature (1988) 1.67
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov (2012) 1.62
Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol (2004) 1.59
Isotype selection in antibody engineering. Nat Biotechnol (2007) 1.57
Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol (1997) 1.53
Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature (2003) 1.53
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol (1993) 1.50
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells (2011) 1.48
Mechanisms of immunotherapy. J Allergy Clin Immunol (2004) 1.45
Structure and flexibility of individual immunoglobulin G molecules in solution. Structure (2004) 1.41
IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods (2005) 1.37
Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol (1986) 1.37
The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol (2001) 1.35
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol (2011) 1.34
Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol (1986) 1.33
A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J (1990) 1.33
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res (2011) 1.32
Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI. Nat Struct Mol Biol (2011) 1.29
T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol (2005) 1.28
The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem (2001) 1.28
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum (2010) 1.25
Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol (2002) 1.25
Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci (1997) 1.24
Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr (2008) 1.24
Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol (2000) 1.23
Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol (2011) 1.23
IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol (2015) 1.22
Structure and function relationships in IgA. Mucosal Immunol (2011) 1.18
IgG4- related disease: an orphan disease with many faces. Orphanet J Rare Dis (2014) 1.17
Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci U S A (2013) 1.17
Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells. J Immunol (2006) 1.13
Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem (2011) 1.12
The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies. Mol Immunol (1987) 1.12
IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 1.12
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med (1991) 1.12
Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem (2004) 1.11
Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem (2014) 1.10
IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol (2005) 1.10
Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure (2011) 1.10
CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res (2011) 1.09
Structure of the murine unglycosylated IgG1 Fc fragment. J Mol Biol (2009) 1.09
Structure and dynamics of IgE-receptor interactions: FcεRI and CD23/FcεRII. Immunol Rev (2015) 0.78